We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,636.00 | 1,638.00 | 1,639.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.69 | 67.46B |
By Kathryn Hardison
International stocks trading in New York closed mostly higher Friday.
The S&P/BNY Mellon index of American depositary receipts rose 0.2% to 144.57. The European index moved 0.1% higher to 139.55, the Asian index rose 0.6% to 167.49, the Latin American index fell 0.1% to 189.44 and the emerging markets index increased 0.9% to 284.29.
H World Group Ltd. and RedHill Biopharma were among the companies with ADRs that traded actively.
ADRs of H World Group increased 5.9% on Friday following news that Hui Chen will step down as finance chief of the company, effective immediately. The company said Jihong He, its chief executive for international business, has been appointed as its new CFO.
ADRs of RedHill Biopharma dropped 27% after the company priced an $8 million underwritten public offering. The offering is expected to close Dec. 6.
ADRs of GSK PLC increased 0.9% after the pharmaceutical company said a Phase 3 trial for its Jemperli treatment for advanced or recurrent endometrial cancer met its primary endpoint, showing meaningful improvement in progression-free survival.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
December 02, 2022 17:22 ET (22:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions